NeuroSolis, Inc.
- Biotech or pharma, therapeutic R&D
NeuroSolis develops pre-clinical drug candidates for treatment of neurological disorders. Our first candidate was successfully partnered and is undergoing a large phase II trial. We are currently developing a lead-optimized, selective GABA receptor agonist for possible indications of migraine, tic disorders. trigeminal neuralgia, schizophrenia and essential tremor.
Address
MadisonWisconsin
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}